Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Gilead Sciences (NQ: GILD)
74.84 USD  -2.47 (-3.19%)
Official Closing Price  /  Updated: 7:13 PM EDT, Aug 15, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 11,810,000
Open 76.40
Bid (Size) 74.78 (2)
Ask (Size) 74.99 (1)
Prev. Close 77.31
Today's Range 74.25 - 76.47
52wk Range 64.27 - 89.54
Shares Outstanding 1,300,260,832
Dividend Yield 2.91%
Performance
YTD
+1.00%
+1.00%
1 Month
-3.13%
-3.13%
3 Month
+10.79%
+10.79%
6 Month
-8.53%
-8.53%
1 Year
+2.35%
+2.35%
Top News
More News
Gilead Skids On HIV Rivalry As Second Exec In A Month Plans Exit
Gilead Sciences toppled Wednesday after rival GlaxoSmithKline reported positive results from an HIV drug study and following the announcement a key executive will depart next month. Read More
from Investor's Business Daily
Gilead Sciences Announces Executive Promotions
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase... Read More
from Business Wire News Releases
More News
Read More
Stocks Showing Improved Relative Strength: Gilead Sciences
from Investor's Business Daily
UPDATE 2-Long-acting injection a shot in the arm for GSK's HIV business
category companyNews
from Reuters: Company News
UPDATE 1-Long-acting injection a shot in the arm for GSK's HIV business
category companyNews
from Reuters: Company News
Long-acting injection boosts hopes for GSK's HIV business
category companyNews
from Reuters: Company News
UPDATE 3-Congo deploys experimental Ebola treatment as cases rise
category companyNews
from Reuters: Company News
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2018 Financial Results
from Business Wire News Releases
UPDATE 2-Congo starts using experimental Ebola treatment
category companyNews
from Reuters: Company News
UPDATE 1-Congo starts using experimental Ebola treatment
category companyNews
from Reuters: Company News
GILD a Top 25 Dividend Giant With $5.23B Held By ETFs
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.